Management and Development
Chief Executive Officer. Kristofer is an experienced professional with a diverse skill set in areas such as software development, product management, marketing, sales, innovation and general management. He has 18 years of industrial experience from the cancer diagnostics and therapy fields.
Karin Hartman Lindgren
Chief Operating Officer. Karin has a MCs in Biomedicine and a BA in Financial accounting from Uppsala University. With training in both business administration and biomedicine, Karin brings important competence in business and enterprise in the life science sector. Karin has experience from manufacturing, development, and sales and marketing in start-up companies in the medical device industry.
Chief Technology Officer. Ivaylo blends experience from cancer genetics with a passion for software development. He did a PhD in molecular genetics at Stockholm University and did his post-doc in cancer genetics at Uppsala University before co-founding Oncodia.
Core Developer. Marina has a MSc in bioinformatics from Uppsala University with a focus on the quality control of next-generation sequencing data. After successful translation of her NGS experience from academia to the Oncodia’s team, Marina dedicated to the core development and building of the software production standards in the company.
Regulatory Implementation Manager and Core Developer. Tom has a MSc in molecular biotechnology engineering from Uppsala University, and a degree in computer science from Göteborg University. He has experience from software development in different sectors, such as the stock exchange (Syncom Financial Systems), electricity market (ABB), biotech (Biacore AB) and somatic mutation calling (UU).
Production Manager NGEx product line. Linnea has extensive knowledge in the field of nucleic acid extractions from a variety of biological sources. She got her MSc from Uppsala University in the field of molecular-/cell biology and has since worked in both pharmaceutical industry as well as university settings. Linnea joined Oncodia following the acquisition of ExScale Biospecimen Solutions in late 2019, and is now responsible for production and development of NGEx products.
Board of Directors
is the Chairman of Oncodia. He brings 40 years of leadership experience from the medical device industry, including board roles in 15 companies in Sweden, Germany and the US. He was co-founder and Chairman of the publicly traded companies RaySearch and CEO of C-Rad, and is currently Chairman of Pharmacolog AB. He is also Chairman of Nolsterby Invest AB.
Professor of Tumor Genetics at Uppsala University. He pioneered exome sequencing in cancer and the science powering Oncodia’s products was developed in his group at Uppsala University.
Investment manager at Uppsala University Holding AB. Mateo is a business developer and investment professional with 15 years of experience of academic startups, and has been involved in the strategic and operational management of several successful Uppsala University spin-offs.
Chairman and founder of Didner & Gerge Fonder. He has a PhD in Business Studies from Uppsala University. After the dissertation he left the university and started with a colleague the fund management company Didner & Gerge Fonder. Henrik has an interest in early start-ups and have invested in a number of companies, mostly in life science and technology.
CEO of Novus Scientific. Henrik brings more than 15 years of experience from various roles within the medical device industry, including development, marketing and sales. He has focused most of his career on global market introductions of innovative medical technologies including products such as TIGR Matrix and OssDsign Cranial PSI.